glp 1 companies in usa What is the future of GLP-1 trends: PwC GLP-1 Market Size to Hit

Among non-elderly adults with ESI (estimated to be 116.8 million from NHIS), 42%, or 49.3 million people, are clinically eligible for GLP-1 drugs

Sustainability of Weight Loss One of the common concerns about GLP-1 medications is the sustainability of weight loss after discontinuation

It works in a similar way to injectable GLP-1 receptor agonists like Wegovy and Mounjaro, but in a pill form that does not require refrigeration or needles

Research Linking GLP-1 Medications to Stomach Paralysis A study from the University of British Columbia has found a link between GLP-1 medications and gastroparesis

Their medications are compounded, not FDA-approved, which is standard for this category of provider